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Contractile Reserve:
Are We Beginning to Understand It?*
Gary S. Francis, MD, FACC, Milind Y. Desai, MD
Cleveland, OhioThe concept of contractile reserve is an old idea
garnered from observations made by many investi-
gators over the years. Various techniques have been
used to study left ventricular (LV) performance in
either the true failing heart or the heart with
impaired systolic function, including post-systolic
accentuation, epinephrine ventriculography, and
various hemodynamic and echocardiographic re-
sponses to direct inotropic stimulation with dobut-
amine (1–3). The idea behind the test is to provide
an objective means of determining the point at
which the patient’s heart has irreversibly failed. The
identification of irredeemable heart damage could
(for example) allow the physician to refer the patient
for heart surgery or heart transplantation.
See page 718
In this issue of iJACC, Kobayashi et al. (4) have
further investigated the basis of diminishment in
contractile reserve in 46 asymptomatic or mildly
symptomatic patients with dilated cardiomyopathy.
Patients were classified depending on their response
of dP/dt max to dobutamine, as well as on the basis
of their baseline ejection fraction. Plasma norepi-
nephrine and myocardial [123I] metaiodobenzylgua-
nidine scans were obtained, and an LV biopsy was
done to characterize a number of molecular markers
associated with the inotropic state. Patients less
responsive to dobutamine demonstrated more ab-
normalities of sympathetic activity (higher plasma
norepinephrine levels or less myocardial catechol-
amine tissue density) despite a similarly reduced
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.From the Heart and Vascular Institute, Cleveland Clinic, Cleveland,
Ohio.ejection fraction. These patients also had evidence
for reduced molecular markers of LV contractile
state, indirectly assessed by measuring messenger
ribonucleic acid from LV biopsies. This raises the
possibility of using noninvasive imaging to character-
ize and possibly type subsets of intracellular abnormal-
ities that underlie contractile dysfunction in the future.
However, the longstanding and vexing question
of what is driving the central theme of heart failure
remains. Are the abnormal molecular markers a
consequence of the impaired myocardial function,
or are the molecular changes actually causing the
decreased LV function? As the authors point out,
markers such as myocardial tissue norepinephrine
has long been known to be depleted in human
failing hearts (5), and this is usually accompanied by
increased plasma levels of norepinephrine (6). Like-
wise, numerous previous studies have demonstrated
reduced beta-adrenergic receptors along with al-
tered sarcoplasmic reticulum Ca2-adenosine
triphosphatase 2a (SERCA2a) and phospholamban
in failing hearts (7). The fact that these changes
were observed in relatively early stages of heart
failure, and were more marked in those patients
with reduced myocardial contractile reserve, would
suggest that changes observed at the molecular level
may actually be the cause of at least some of the
impairment in LV function. Likewise, blocking the
sympathetic nervous system at the beta-receptor
level or replacing SERCA2a with gene therapy can
reverse the reduced contractile state, thus fulfilling
at least one of Koch’s postulates.
Assuming that a more noninvasive approach to
defining “contractile reserve” or some surrogate
thereof in patients with heart failure is preferable, is
there a need and a real benefit from such measure-
ments? If so, what is the current status of such
noninvasive approaches? Most cardiologists would
like to know if there is such a point from which a
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Editorial Comment
728eturn to more normalcy is either likely or not likely.
f course, this will always be a probability estimate,
ince no such test is likely to be precise in an
ndividual patient. Moreover, for patients being
onsidered for heart surgery, predicting which LV
ill recover depends to some extent on the quality
f the operation in addition to the basal inotropic
tate of the LV before surgery. Nevertheless, such a
eed for defining “recoverability” seems self-
vident. Two classic examples are patients with
evere cardiomyopathy and severe regurgitant val-
ular disease, or patients with low gradient aortic
tenosis and very poor LV function. This area needs
uch further study, and the study of Kobayashi et
l. (4) is only a start in this direction.
In summary, estimating contractile reserve in
atients with impaired LV function is worthwhile,reserve is unrelated to basal systolic
gestive heart failure.
39:442–51.urgery, coronary revascularization, and candidacy
or heart transplantation. The basis for contractile
eserve probably resides in several molecular mark-
rs of contractility, including beta-receptor density,
ltered SERCA2a, and phospholamban, as mea-
ured by myocardial biopsy by Kobayashi et al. (4).
maging of molecular markers is on the horizon, but
ntil it is more routine, cardiologists will continue
o rely on those techniques that are performed in
heir own hospital laboratories with the most ex-
ertise and experience. For many, this will include
he traditional assessment of contractile reserve.
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